secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2022-02-10T23:59:59+00:00
Accession:  0001193125-22-033574
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir reports FY2021 net loss $172M; cash $248.1M; three Phase 3 trials advancing
--------------------------------------------------------------------------------

- Net loss $172.0M ($2.74/share) for 2021 vs. $69.8M in 2020; cash $248.1M at year-end.
- Three Phase 3 registrational studies of posoleucel: HC, AdV treatment enrolling; multi-virus prevention expected 1H22.
- R&D expenses $120.7M in 2021; 2022 operating expense guidance $130-145M (excl. stock comp).
- ALVR106 Phase 1/2 for respiratory viruses initiated Dec 2021; ALVR107 preclinical for hepatitis B ongoing.
- Initial data from posoleucel BK viremia POC study in kidney transplant expected 1H22.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522033574/0001193125-22-033574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312522033574/d196801d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-033574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer